Year: 2008
Type: article
Abstract: The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a longitudinal multisite observational study of healthy elders, mild cognitive impairment (MCI), and Alzheimer's disease. Magnetic resonance imaging (MRI), (18F)-fluorodeoxyglucose positron emission tomography (FDG PET), urine serum, and cerebrospinal fluid (CSF) biomarkers, as well as clinical/psychometric assessments are acquired at multiple time points. All data will be cross-linked and made available to the general scientific community. The purpose of this report is to describe the MRI methods employed in ADNI. The ADNI MRI core established specifications that guided protocol development. A major effort was devoted to evaluating 3D T(1)-weighted sequences for morphometric analyses. Several options for this sequence were optimized for the relevant manufacturer platforms and then compared in a reduced-scale clinical trial. The protocol selected for the ADNI study includes: back-to-back 3D magnetization prepared rapid gradient echo (MP-RAGE) scans; B(1)-calibration scans when applicable; and an axial proton density-T(2) dual contrast (i.e., echo) fast spin echo/turbo spin echo (FSE/TSE) for pathology detection. ADNI MRI methods seek to maximize scientific utility while minimizing the burden placed on participants. The approach taken in ADNI to standardization across sites and platforms of the MRI protocol, postacquisition corrections, and phantom-based monitoring of all scanners could be used as a model for other multisite trials.
DOI: 10.1002/jmri.21049
Authors: Clifford R. Jack, Matt A. Bernstein, Nick C. Fox, Paul Thompson, Gene Alexander, Danielle Harvey, Bret Borowski, Paula J. Britson, Jennifer L. Whitwell, Chadwick Ward, Anders M. Dale, Joel P. Felmlee, Jeffrey L. Gunter, Derek L.G. Hill, Ron Killiany, Norbert Schuff, Sabrina Fox‐Bosetti, Chen Lin, Colin Studholme, Charles S. DeCarli, Gunnar Krueger, Heidi A. Ward, Gregory J. Metzger, Katherine T. Scott, Richard Mallozzi, Daniel Blezek, Joshua Levy, Josef P. Debbins, Adam S. Fleisher, Marilyn Albert, Robert Green, George Bartzokis, Gary Glover, John Mugler, Michael W. Weiner
Institutions: Mayo Clinic, National Hospital for Neurology and Neurosurgery, University of California, Los Angeles, Arizona State University, University of California, Davis, University of California San Diego, University College London, Boston University, San Francisco VA Medical Center, University of California, San Francisco, General Electric (United States), Philips (Netherlands), Johns Hopkins University, Johns Hopkins Medicine, Massachusetts General Hospital, Stanford Medicine, Stanford University, University of Virginia
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Foundation for the National Institutes of Health, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Alzheimer's Disease Neuroimaging Initiative, Novartis Pharmaceuticals Corporation, Elan, Eisai, National Institutes of Health, U.S. Food and Drug Administration, National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering
Awards: G104586243, UC Davis Alzheimer's Disease Core Center, G1557667123, G2835601961, G29951154, G3131374986, G3146424788, G3553156159, G3705772492, G3710456697, G43180419, G5207404921, G5209990037, G5389965057, G613619302, G6259281481, G6899163935, G7414321945, G7799614282, G781725486, G839208290, G9000039018, G9000122335, G920654007
OpenAlex ID: W2078524519